Buprenorphine And Naloxone
Generic Name: buprenorphine and naloxone
Brand Names:
Buprenorphine And Naloxone
Buprenorphine and naloxone sublingual film is indicated for the treatment of opioid dependence as part of a comprehensive treatment plan including counseling and psychosocial support.
Overview
Buprenorphine and naloxone sublingual film is indicated for the treatment of opioid dependence as part of a comprehensive treatment plan including counseling and psychosocial support.
Uses
Indicated for treatment of opioid dependence. Should be part of a comprehensive treatment plan including counseling and psychosocial support.
Dosage
Administered as a single daily dose sublingually or buccally. Initial induction dosing for short-acting opioid dependence: up to 8 mg/2 mg on Day 1, up to 16 mg/4 mg on Day 2. Target maintenance dose: 16 mg/4 mg daily. Film must be administered whole and allowed to completely dissolve.
Side Effects
Most common adverse reactions include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, and withdrawal symptoms. Serious reactions include respiratory depression and hepatic events.
Interactions
Significant interactions with benzodiazepines, CYP3A4 inhibitors/inducers, antiretrovirals, serotonergic drugs, and MAOIs.
Warnings
Risks of respiratory depression, CNS depression with benzodiazepines, pediatric exposure dangers, neonatal withdrawal syndrome, adrenal insufficiency, hepatic complications, and dental adverse events. Contraindicated in hypersensitivity to buprenorphine or naloxone.
Frequently Asked Questions
What is Buprenorphine And Naloxone used for?▼
Indicated for treatment of opioid dependence. Should be part of a comprehensive treatment plan including counseling and psychosocial support.
What are the side effects of Buprenorphine And Naloxone?▼
Most common adverse reactions include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, and withdrawal symptoms. Serious reactions include respiratory depression and hepatic events.
What are the important warnings for Buprenorphine And Naloxone?▼
Risks of respiratory depression, CNS depression with benzodiazepines, pediatric exposure dangers, neonatal withdrawal syndrome, adrenal insufficiency, hepatic complications, and dental adverse events. Contraindicated in hypersensitivity to buprenorphine or naloxone.
Related Medications
Lamivudine, Nevirapine, And Stavudine
lamivudine, nevirapine, and stavudine
Manufactured by MACLEODS PHARMA. Dosage form: TABLET. Route: ORAL. Active ingredients: LAMIVUDINE, NEVIRAPINE, AND STAVUDINE (150MG). Application: NDA022537.
Aspirin And Extended-release Dipyridamole
aspirin and extended-release dipyridamole
Nonsteroidal Anti-inflammatory Drug [EPC]
11 DESCRIPTION Aspirin and extended-release dipyridamole is a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole, USP in an extended-release form and 25 mg aspirin USP, as an immediate-release sugar-coated tablet.
Mercurius Dulcis
mercurius dulcis
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.